SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of July 2023
(Commission File No. 001-41636)
Oculis Holding AG
(Translation of registrants name into English)
(Address of registrants principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On July 6, 2023, pursuant to Section 9.10 of the Business Combination Agreement dated October 17, 2022, by and among European Biotech Acquisition Corp. and Oculis SA (the Business Combination Agreement), Oculis SA and Oculis Operations GmbH, each a wholly-owned subsidiary of Oculis Holding AG (the Registrant), completed the Third Merger (as defined in the Business Combination Agreement). At the time of the Third Merger, Oculis SA merged with and into Oculis Operations GmbH, the separate corporate existence of Oculis SA ceased. Oculis Operations GmbH remains a wholly owned subsidiary of the Registrant.
The information contained in this Form 6-K is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Oculis Holding AG|
|Date: July 6, 2023||
|By:||/s/ Sylvia Cheung|
|Name: Sylvia Cheung|
|Title: Chief Financial Officer|